% | $
Quotes you view appear here for quick access.

Affymax, Inc. Message Board

  • dinepat203 dinepat203 Apr 18, 2013 12:30 PM Flag


    All reported reactions were only from Fresenius dialysis Centers where as Omontys were used by DaVita and 100 other MDOS.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thank you....I will read it.

      Sentiment: Strong Buy

    • Anemia Drug Is Recalled After Allergic Reactions
      Published: February 24, 2013


      The big question is whether this will cause the drug to be withdrawn from the market. It is possible that doctors can act to avert or lessen allergic reactions on the first dose. It is also possible the problems are confined to certain dialysis centers.

    • Sources please....?

      Sentiment: Strong Buy

      • 1 Reply to yale1066
      • Sources every where, Problem is why Orwin did not mentioned this during first PR that only The recalled lots of the medicine is 10mg Multi-dose vials, Lots - C18685, C18881, C19258, 20mg Multi-dose vials, Lots - C18686, C18696. These were supplied to Fresenius Medical Care facilities.

        So it is unclear why such silence from company's CEO on important information.

    • I find that VERY interesting...Please post your sources. How many dialysis centres were using Omontys before the deaths and did any of them raise ANY concerns ?

      Sentiment: Strong Buy

      • 1 Reply to yale1066
      • Dear Colleagues:

        We are writing to provide an interim update on the status of our pilot to assess the use of OMONTYS® in the FMCNA dialysis facilities. The purpose of the commercial pilot is to determine the role of OMONTYS® as an alternative Erythropoiesis Stimulating Agent (ESA) on the FMCNA Formulary. The assessment includes efficacy, safety and logistics related to this agent that was approved for use by the Food and Drug Administration at the end of March 2012.

        We will now pause expansion of the pilot that began in late July 2012. We have accumulated experience in more than 56,600 administrations in over 18,000 unique patients. Two months into the FMCNA pilot program, the FDA released revised product information that added language similar to the prescribing information for EPOGEN® concerning the risk for allergic reactions, which we communicated to you in November 2012. To date, we have seen infrequent allergic reactions in our patient population receiving their first dose of OMONTYS®. Most of these reactions have been mild, but a small number have been serious. The rate of allergic reactions has been on the order of 1:1000 patients receiving a first dose of OMONTYS®. The vast majority of patients who are receiving the medication on an ongoing monthly basis are tolerating it well.

        We are now working to analyze the full set of efficacy and safety profile information and feel that the current scale of our experience with use of the drug is adequate to complete this analysis. These results will be presented to our Corporate Medical Advisory Board with follow up reporting to our medical staff. In the meantime, this communication is to inform you of our confirmation of the adjusted prescribing information and the finding that such allergic reactions can occur in patients receiving the first dose of the drug. For patients on OMONTYS®, we recommend continued use of the agent as it has been providing effective anemia management. We plan to pause the rollout to additional facilities and patients at this time until the analyses are complete and reported to our medical staff. As many of you have become quite comfortable with the medication, physicians and facilities that have been using OMONTYS® who wish to continue prescribing it for new patients may choose to do so.

        As we complete the analysis in the next week or two we plan to provide an update on the pilot experience and any future recommendations. I thank you for your participation in determining best protocols and practices around the use of OMONTYS® and we will update you with the analysis of our experience once complete.

        With best regards,

        Franklin W. Maddux, MD, FACP
        Chief Medical Officer
        Executive VP For Clinical and Scientific Affairs
        Fresenius Medical Care North America

        Jeffrey L. Hymes, MD
        Associate Chief Medical Officer

        Fresenius Medical Care North America

    • And how do you know this? The adverse reactions were voluntarily reported to the FDA by prescribing doctors and clinics. It is true that Fresenius is the only publicly disclosed facility that reported adverse events. There is no way to tell if only Fresenius involved. The WSJ article, based on a FOIA request, reported problems arose immediately as Omontys introduced into US market.

    • Cancel -Fresenius Medical Care License to operate in USA
      US AntiTrust Laws: Although monopolies are illegal under U.S. law, there are some companies that still have virtual monopolies in their industries. These companies dominate their respective markets and have no significant competitor. Their revenues in their markets dwarf those of the closest competitors.

    • Fresenius said Feb. 14 it was working to "analyze the full set of efficacy and safety profile information" on Omontys after more than 56,000 doses in about 18,000 patients. "We ... feel that the current scale of our experience with use of the drug is inadequate to complete this analysis," the company said in a letter.

      Ten days ago, the dialysis provider Fresenius said it would stop expanding an Omontys pilot program, after seeing "infrequent" allergic reactions in patients after their first dose. A "small number" of those were serious, the company said in a letter filed with the Securities and Exchange Commission

0.061-0.0088(-12.54%)Aug 26 10:53 AMEDT